I’ll not belabor it, but for Q4, the company may post a slight decline in quarterly earnings — but all of that will very likely be reversed here in 2026. [So that headline… is a bit of a red herring.] Gilead reports tomorrow morning.

[Yep — this is just a quick “power alley” cut and paste job. Heh.] Here’s the latest:

…The consensus EPS Estimate is $1.83 on revenue of $7.68B, which translates to a 1.5% jump compared to the corresponding quarter a year ago.

Seeking Alpha analyst Narek Hovhannisyan expects the company to outperform market expectations, driven by strong demand for its core drugs and controlled costs. Over the last 2 years, GILD has beaten EPS and revenue estimates 88% of the time.

UBS holds an extremely optimistic view of the company for FY26 on expectations of strong HIV PrEP sales from Yeztugo, which, analysts say, are likely to drive revenue and earnings growth and boost confidence in longer-term performance….

Beyond its core business, Gilead has moved into a more measured phase of dealmaking, focusing on strengthening its oncology and immunology pipelines, analysts at Bernstein noted.

“They continue to highlight Cymabay style deals ($4.3B in PBC – liver/inflammation). This scale of deal & spend aligns with investor’s willingness to see Gilead diversify,” UBS analyst Courtney Breen said….

Now you know — onward, into the chilly glass canyons — to find excellent bespoke chocolate delights. Smile.

नमस्ते